The FDA and the Next Wave of Drug Abuse — Proactive Pharmacovigilance

In responding to the opioid crisis, the FDA needs to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow the agency to intervene promptly and appropriately to protect the public from associated risks.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2018-07, Vol.379 (3), p.205-207
Hauptverfasser:	Throckmorton, Douglas C, Gottlieb, Scott, Woodcock, Janet
Format:	Artikel
Sprache:	eng
Schlagworte:	Addictions Amines - therapeutic use Analgesics Analgesics, Opioid - adverse effects Analgesics, Opioid - therapeutic use Cyclohexanecarboxylic Acids - therapeutic use Disclosure Drug abuse Drug dosages Drug Therapy, Combination - adverse effects Drug use Drug Utilization - trends FDA approval Gabapentin gamma-Aminobutyric Acid - therapeutic use Humans Loperamide - adverse effects Loperamide - therapeutic use Narcotics Opioid-Related Disorders - prevention & control Opioid-Related Disorders - therapy Opioids Pain Pharmacovigilance Practice Patterns, Physicians' - trends Prescription drugs Prescription Drugs - therapeutic use Secologanin Tryptamine Alkaloids - therapeutic use Social networks Substance abuse treatment Substance-Related Disorders - prevention & control Trends United States United States Food and Drug Administration
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In responding to the opioid crisis, the FDA needs to recognize shifting trends in the addiction landscape. Taking a systematic approach to monitoring such trends should allow the agency to intervene promptly and appropriately to protect the public from associated risks.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMp1806486